doi: 10.1016/j.bjhh.2016.07.006.
Epub 2016 Sep 9.
Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide, thalidomide, and dexamethasone: is granulocyte-colony stimulating factor alone enough?
Affiliations
- PMID: 27863752
- PMCID: PMC5119658
- DOI: 10.1016/j.bjhh.2016.07.006
Item in Clipboard
Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide, thalidomide, and dexamethasone: is granulocyte-colony stimulating factor alone enough?
Rev Bras Hematol Hemoter.
2016 Oct-Dec.
No abstract available
Similar articles
-
Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?Rev Bras Hematol Hemoter. 2016 Oct-Dec;38(4):302-309. doi: 10.1016/j.bjhh.2016.06.004. Epub 2016 Jul 29. Rev Bras Hematol Hemoter. 2016. PMID: 27863757 Free PMC article.
-
Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.J Clin Apher. 2016 Oct;31(5):423-8. doi: 10.1002/jca.21421. Epub 2015 Sep 5. J Clin Apher. 2016. PMID: 26340986
-
Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.Biol Blood Marrow Transplant. 2004 Jun;10(6):395-404. doi: 10.1016/j.bbmt.2004.02.001. Biol Blood Marrow Transplant. 2004. PMID: 15148493 Clinical Trial.
-
High intensity regimens with autologous hematopoietic stem cell transplantation as treatment of multiple myeloma.Ann Transplant. 2002;7(2):38-43. Ann Transplant. 2002. PMID: 12416471 Review.
-
A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents.Bone Marrow Transplant. 2003 Dec;32(12):1113-7. doi: 10.1038/sj.bmt.1704286. Bone Marrow Transplant. 2003. PMID: 14647264 Review.
Cited by
-
The impact of multiple myeloma induction therapy on hematopoietic stem cell mobilization and collection: 25-year experience.Hematol Transfus Cell Ther. 2019 Oct-Dec;41(4):285-291. doi: 10.1016/j.htct.2019.03.005. Epub 2019 Jun 14. Hematol Transfus Cell Ther. 2019. PMID: 31412990 Free PMC article.
References
-
- Shah N., Callander N., Ganguly S., Gul Z., Hamadani M., Costa L. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2015;21:1155–1166. - PubMed
-
- Giralt S., Stadtmauer E.A., Harousseau J.L., Palumbo A., Bensinger W., Comenzo R.L. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) Leukemia. 2009;23:1904–1912. - PubMed
-
- Bensinger W., DiPersio J.F., McCarty J.M. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant. 2009;43:181–195. - PubMed
-
- Crusoe E.Q., Higashi F., Martinez G.A., Barros J.C., Bellesso M., Rossato M. Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen? Rev Bras Hematol Hemoter. 2016;38 - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
